The purpose of the trial is to identify a safe and effective dose of the new medication, to see how well it works against these cancers, and to understand how it interacts with other treatments. Early parts of the study increase the dose to find the highest amount patients can tolerate, followed by later parts that treat specific cancer types either alone or combined with the listed drugs. A small group of participants will also receive medicines that are processed by the enzymes CYP3A4 and CYP2C8 to check for possible drug‑interaction effects.

Participants will take the study tablet each day and receive the other medicines by intravenous infusion, meaning the drugs are given through a vein. Regular clinic visits will include physical checks, blood tests, and imaging scans that are evaluated using RECIST criteria, a system that measures how tumor size changes over time. The trial will continue for several months, with close monitoring for side effects, dose adjustments if needed, and assessments of tumor response.

The purpose of this research is to determine if BNT326 is safe and potentially helpful when used alone or in combination with other cancer treatments, including BNT327. The study is divided into two parts. In the first part, participants receive only BNT326. In the second part, participants receive BNT326 together with other cancer treatments that help the immune system fight cancer cells.

During the study, doctors will monitor how participants respond to the treatment and check for any side effects. The medications will be given through an infusion into a vein at a medical facility. Participants will need to visit the medical center regularly for treatment and health evaluations. The study team will track how the tumors respond to treatment using various medical tests and imaging.

The purpose of the study is to find out how safe and tolerable BDC-1001 is when used alone and when combined with nivolumab. The study will also look at how well these treatments work against the cancer. The study is divided into different parts. In the first part, patients will receive BDC-1001 alone to see how their bodies react to it. In the second part, patients will receive both BDC-1001 and nivolumab to see if the combination is safe and effective. Later parts of the study will focus on how well the treatments work in shrinking the tumors or stopping them from growing.

Participants in the study will receive the treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor patients closely to check for any side effects and to see how the cancer responds to the treatment. The goal is to find the best dose of BDC-1001 that can be used safely and effectively, both on its own and with nivolumab, for treating advanced HER2-expressing solid tumors.

The study is divided into two phases. In the first phase, participants will receive increasing doses of Livmoniplimab to determine the most suitable dose. In the second phase, the focus will be on evaluating the effectiveness of the combination of Livmoniplimab and Budigalimab in treating specific types of solid tumors. Participants will receive the medications through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

The trial will monitor participants for any side effects and measure how the medications affect their tumors. The study will also look at how long the response to the treatment lasts and how long participants live without their disease getting worse. This research is important for understanding how these new treatments might help people with advanced solid tumors in the future.

The purpose of the study is to find the best dose of BNT314 that can be safely given to patients and to see how well it works against cancer. The study will start with a phase called dose escalation, where different doses of BNT314 will be tested to find the maximum amount that can be given without causing severe side effects. After this, the study will move to a phase called dose expansion, where more patients will receive the treatment to gather more information about its safety and effectiveness. Some patients will receive BNT314 alone, while others will receive it in combination with pembrolizumab.

Throughout the study, patients will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential of BNT314 as a new treatment option for people with advanced cancer. The trial is expected to continue until 2027, with recruitment of participants starting in late 2023. Participants will receive regular check-ups and assessments to ensure their safety and to track the progress of their treatment.

The purpose of the study is to determine the best dose of entrectinib for children and to evaluate how effective it is in treating these tumors. The study will involve taking the medication in different forms, such as capsules or granules, which can be swallowed or given through a feeding tube. The study will also look at how the body processes the medication and any side effects that may occur. The study will assess the response of the tumors to the treatment using specific criteria designed to measure changes in tumor size and growth.

Participants in the study will receive either entrectinib or a placebo, and their health will be closely monitored throughout the trial. The study will help researchers understand how well entrectinib works in treating these types of tumors in children and adolescents, and it will provide valuable information on the safety and effectiveness of the medication. The trial is expected to continue until 2026, with the goal of improving treatment options for young patients with these challenging conditions.

Participants in the study will receive either BMS-986449 by itself or in combination with nivolumab. The study will monitor how the body responds to these treatments and any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study will help researchers learn more about how these treatments work in the body and their potential benefits for people with advanced cancer.

The trial will take place over a period of time, during which participants will have regular check-ups and tests to monitor their health and the effects of the treatments. The information gathered from this study will contribute to understanding the potential of BMS-986449 and nivolumab as treatment options for advanced solid tumors, providing valuable insights for future cancer therapies.